Meridian Bioscience (VIVO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $2.36 --0%
Financial Fact:
Total other income (expense): -143K
Today's EPS Names:
SYRS, ZVOI, OMID, More
Financial Fact:
Total other income (expense): -143K
Today's EPS Names:
SYRS, ZVOI, OMID, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.20, $0.03 better than the analyst estimate of $0.17. Revenue for the quarter came in at $51.5 million versus the consensus estimate of $53.1 million.
GUIDANCE:
Meridian Bioscience sees FY2019 EPS of $0.74-$0.76, versus the consensus of $0.76.
- Net revenues Flat-2% growth
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Check Point Software Technology (CHKP) Reports In-Line Q3 EPS
- Raymond James Reiterates Strong Buy Rating on Willis Towers Watson (WTW)
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
